While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck cancer.
Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients. Keytruda ...
Sign Up for Wine Spectator’s Free Email Newsletters and stay up-to-date with all things wine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback